Overview of FOLFOXIRI plus panitumumab for selected colorectal cancer patients

July 06, 2022

1 minute watch


Source: Cremolini C, et al. Abstract LBA3505. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.

Disclosures: Cecchini does not report any relevant financial information.

We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

In this video, Michael CecchiniMD, discussed a late-breaking abstract evaluating FOLFOXIRI plus panitumumab vs mFOLFOX6 plus panitumumab as initial therapy for unresectable patients RAS and BRAF wild-type metastatic colorectal cancer.

“There was no increase in response rate, which was their primary endpoint, despite being a phase 3 study with over 400 patients; also no significant improvement in PFS or SG,” Cecchini, an assistant professor of medical oncology at the Yale School of Medicine, said of the study presented at the ASCO annual meeting.

“This shows us that FOLFOXIRI plus panitumumab or FOLFOXIRI potentially with cetuximab is not really a treatment that we should routinely offer our patients,” Cecchini said.

Comments are closed.